Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Skybiotech Healthcare's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 55.23.
Skybiotech Healthcare's Days Inventory for the
three
months ended in Mar. 2026 was 54.52.
Skybiotech Healthcare's Days Payable for the
three
months ended in Mar. 2026 was 57.85.
Therefore, Skybiotech Healthcare's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 51.90.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Skybiotech Healthcare Cash Conversion Cycle Related Terms
Skybiotech Healthcare Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Skybiotech Healthcare's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:512036 vs MMM, HON: Cash Conversion Cycle Comparison
For the Conglomerates subindustry, Skybiotech Healthcare's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skybiotech Healthcare Cash Conversion Cycle vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Skybiotech Healthcare's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Skybiotech Healthcare's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Skybiotech Healthcare's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skybiotech Healthcare (BOM:512036) has a Cash Conversion Cycle of 51.90 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Skybiotech Healthcare and its competitors.
Is Skybiotech Healthcare's Cash Conversion Cycle too high?
Skybiotech Healthcare's current Cash Conversion Cycle is 51.90. The Conglomerates industry median Cash Conversion Cycle is 73.62. Skybiotech Healthcare's value of 51.90 is 29.5% below this industry median. Overall, Skybiotech Healthcare has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Skybiotech Healthcare's Cash Conversion Cycle compare to MMM and HON?
Skybiotech Healthcare's Cash Conversion Cycle of 51.90 can be compared against companies in the Conglomerates industry. The industry median Cash Conversion Cycle is 73.62. Skybiotech Healthcare's value of 51.90 is 29.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Conglomerates company?
The median Cash Conversion Cycle among Conglomerates companies is 73.62, based on 539 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Skybiotech Healthcare's current Cash Conversion Cycle of 51.90 is 29.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Skybiotech Healthcare and its competitors. For the Conglomerates industry, the median Cash Conversion Cycle is 73.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skybiotech Healthcare's current Cash Conversion Cycle is 51.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skybiotech Healthcare stock overvalued right now?
Skybiotech Healthcare (BOM:512036) has a current Cash Conversion Cycle of 51.90. The current Cash Conversion Cycle is 51.90 and 29.5% below the Conglomerates industry median of 73.62. Skybiotech Healthcare's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Skybiotech Healthcare (BOM:512036), the current Cash Conversion Cycle is 51.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skybiotech Healthcare Ltd, formerly Kapil Cotex Ltd is engaged in textiles and allied products, including dyeing, printing, spinning, weaving, and manufacturing fabrics from raw cotton. During the year under review, the company has not generated any revenue from its core business activities. Instead, it earned income from consultancy services for foreign clients and from investments in shares, generating capital gains and dividends. The company's current revenue mainly comes from these non-core activities rather than textile manufacturing.
23GF Score
Get the complete analysis for BOM:512036
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512036 has been successfully added to your 
